Aldara for the Treatment of Extensive Alopecia Areata

Status Completed

Clinical Trial Summary

We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.

Clinical Trial Description

Ten patients with extensive scalp alopecia areata (>95% hair loss)of less than 2 years duration will be invited to participate in this study. For six months each person will be asked to apply Aldara Cream 5% daily to the right half of the scalp. No drug will be applied to the left side. Skin biopsies will be taken of the right scalp before and at the completion of the therapy. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00177021
Study type	Interventional
Source	University of Minnesota - Clinical and Translational Science Institute
Contact
Status	Completed
Phase	Phase 4
Start date	October 2000
Completion date	August 2002

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05051761` - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata	Phase 3
Active, not recruiting	`NCT03570749` - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	Phase 2/Phase 3
Completed	`NCT02812342` - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2
Completed	`NCT02350023` - Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata	Phase 4
Completed	`NCT02018042` - An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata	Phase 2
Terminated	`NCT01898806` - Intralesional Steroids in the Treatment of Alopecia Areata	Phase 4
Recruiting	`NCT04011748` - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Phase 2
Active, not recruiting	`NCT04517864` - PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA	Phase 2
Not yet recruiting	`NCT05803070` - Topical Cetirizine in Treatment of Localized Alopecia Areata
Not yet recruiting	`NCT05496426` - A Study of KL130008 in Adults With Severe Alopecia Areata	Phase 2
Completed	`NCT04147845` - Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata	N/A
Terminated	`NCT03325296` - Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.	Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Enrolling by invitation	`NCT05745389` - CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2
Not yet recruiting	`NCT06087796` - Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.	Phase 1
Withdrawn	`NCT03532958` - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata	Phase 2
Recruiting	`NCT02604888` - Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females	N/A
Terminated	`NCT01385839` - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata	N/A
Completed	`NCT00408798` - Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin	N/A